718 related articles for article (PubMed ID: 30270406)
1. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Wunderink RG; Giamarellos-Bourboulis EJ; Rahav G; Mathers AJ; Bassetti M; Vazquez J; Cornely OA; Solomkin J; Bhowmick T; Bishara J; Daikos GL; Felton T; Furst MJL; Kwak EJ; Menichetti F; Oren I; Alexander EL; Griffith D; Lomovskaya O; Loutit J; Zhang S; Dudley MN; Kaye KS
Infect Dis Ther; 2018 Dec; 7(4):439-455. PubMed ID: 30270406
[TBL] [Abstract][Full Text] [Related]
2. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
[TBL] [Abstract][Full Text] [Related]
4. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
5. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
Petty LA; Henig O; Patel TS; Pogue JM; Kaye KS
Infect Drug Resist; 2018; 11():1461-1472. PubMed ID: 30254477
[TBL] [Abstract][Full Text] [Related]
6. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
8. Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date.
Herald F; Burgos RM
Infect Drug Resist; 2023; 16():555-568. PubMed ID: 36726388
[TBL] [Abstract][Full Text] [Related]
9. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Lee YR; Baker NT
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
[TBL] [Abstract][Full Text] [Related]
10. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
Shoulders BR; Casapao AM; Venugopalan V
Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections.
Lai CC; Chen CC; Tang HJ
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31614430
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Albin OR; Patel TS; Kaye KS
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
[TBL] [Abstract][Full Text] [Related]
14. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Dhillon S
Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
16. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Patel TS; Pogue JM; Mills JP; Kaye KS
Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
[TBL] [Abstract][Full Text] [Related]
17. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Patient Subgroups in the TANGO II Study.
Bhowmick T
Infect Dis Ther; 2021 Mar; 10(1):35-46. PubMed ID: 33565042
[TBL] [Abstract][Full Text] [Related]
19. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
Wu G; Cheon E
Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
[TBL] [Abstract][Full Text] [Related]
20. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination.
Novelli A; Del Giacomo P; Rossolini GM; Tumbarello M
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):643-655. PubMed ID: 32297801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
